Syndax Pharmaceuticals (SNDX) Other Accumulated Expenses (2015 - 2026)

Syndax Pharmaceuticals' Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 120.49% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (up 120.49% YoY), while the FY2025 annual figure was $721000.0, up 71.26% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.3 million, up from $721000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $3.2 million in Q3 2022, with the low at $208000.0 in Q3 2024.
• The 5-year median for Other Accumulated Expenses is $703000.0 (2023), against an average of $1.0 million.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses surged 1594.68% in 2022, then plunged 83.13% in 2023.
• Syndax Pharmaceuticals' Other Accumulated Expenses stood at $604000.0 in 2022, then surged by 47.02% to $888000.0 in 2023, then sank by 52.59% to $421000.0 in 2024, then soared by 71.26% to $721000.0 in 2025, then surged by 76.14% to $1.3 million in 2026.
• Business Quant data shows SNDX's Other Accumulated Expenses at $1.3 million in Q1 2026, $721000.0 in Q4 2025, and $595000.0 in Q3 2025.